News Sentiment

CTKB sentiment intelligence

Cytek Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 4.62 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.7% over one week, +16.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive 16.7% over four weeks
Fair value -14.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 47
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 12
Stock Titan 9
GlobeNewswire 4
MT Newswires 2
The Globe and Mail 2
www.marketscreener.com 2
StockStory 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 25
Analyst action 4
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
BioSpace Direct company coverage

Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Cytek Biosciences has opened a new innovation center in Bellevue, Washington, relocating its previous Seattle-area operations. This facility is designed to support research and development, strengthen collaboration, and enhance customer engagement, featuring R&D laboratories, ins

Tone
Positive 93/100
Event
Market update
Published
16 Jul 2026 11:40
Source
BioSpace
Stock Titan Direct company coverage

Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms

Cytek Biosciences has detailed the separation terms for its former Chief Legal Officer and Corporate Secretary, Valerie Barnett, whose tenure ended on June 29, 2026. The agreement includes a one-time severance payment of $365,775.12 and COBRA premium coverage, with enhanced benef

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 03:40
Source
Stock Titan
TradingView Direct company coverage

Cytek's Valerie Barnett exits as Chief Legal Officer; consulting role agreed

Valerie Barnett's role as Chief Legal Officer and Corporate Secretary at Cytek terminated on June 29, 2026. She subsequently entered into a severance and consulting agreement in July 2026, which includes a one-time lump sum payment, COBRA premiums, and specific terms for her cons

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:40
Source
TradingView
Stock Titan Direct company coverage

BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences

BlackRock, Inc. has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 9,356,551 shares in Cytek Biosciences, Inc. (CTKB), which represents 7.2% of the outstanding common stock as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 9,2

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 15:41
Source
Stock Titan
AD HOC NEWS Direct company coverage

Cytek Biosciences expands flow cytometry footprint amid growing immunology demand

Cytek Biosciences is expanding its presence in advanced flow cytometry, driven by increasing demand from immunology and cell therapy research. The company's systems and reagents aim to make high-parameter single-cell analysis more accessible, allowing researchers to study complex

Tone
Positive 91/100
Event
Macro sensitivity
Published
07 Jul 2026 16:17
Source
AD HOC NEWS
Finviz Direct company coverage

CTKB - Cytek BioSciences Inc Latest SEC Filings

This article provides a detailed financial overview and snapshot of Cytek BioSciences Inc. (CTKB), including its recent stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights various valuation ratios, sales and ea

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jul 2026 01:09
Source
Finviz
Stock Titan Direct company coverage

If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB)

This article analyzes the historical performance of investing $1,000 in Cytek Biosciences, Inc. (CTKB), a cell analysis solutions company. It details how such an investment would have fared over one year, highlighting a 35% return. The piece also provides an overview of Cytek Bio

Tone
Positive 65/100
Event
Market update
Published
04 Jul 2026 12:10
Source
Stock Titan
Ad-hoc-news.de Direct company coverage

Cytek Biosciences explores growth paths as investors weigh long-term potential

Cytek Biosciences (CTKB, US23284C1053) is a life sciences company developing advanced instruments for cell analysis, particularly focusing on multi-parameter flow cytometry systems. The article highlights that with a thin news cycle, investor attention is on the company's long-te

Tone
Positive 67/100
Event
Market update
Published
03 Jul 2026 20:40
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider

Cytek Biosciences (NASDAQ: CTKB) has filed an initial Form 3 insider ownership report for Ilan Feuchtwang, its new Chief Legal Officer and Secretary. This filing formally establishes Feuchtwang as a reporting insider but does not indicate any stock purchases, sales, or other tran

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 01:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Cytek Biosciences Announces Chief Legal Officer Transition

Cytek Biosciences announced that its Chief Legal Officer and Corporate Secretary, Valerie Barnett, will depart on June 29, 2026, by mutual agreement not related to company operations. An analyst rating for CTKB stock is a Buy with a $4.75 price target, though TipRanks' AI Analyst

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 01:13
Source
The Globe and Mail
TradingView Direct company coverage

Price to sales forward of Cytek Biosciences, Inc. – NASDAQ:CTKB

The article focuses on the "Price to sales forward" metric for Cytek Biosciences, Inc. (NASDAQ: CTKB). It appears to be a stub or a section within a larger financial data platform, likely TradingView, providing financial oversight for the company.

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB

This article provides financial information for Cytek Biosciences, Inc. (NASDAQ: CTKB) focusing on its enterprise value to revenue forward metric. The content appears to be a financial data page from TradingView, displaying the company's stock market data and financial details wi

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 18:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB

This article presents the "Price to earnings forward" value for Cytek Biosciences, Inc. (NASDAQ:CTKB) as part of its financial overview on the TradingView platform. It indicates the period, value, and change metrics for this financial indicator, noting that the data is provided b

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 01:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB

The article discusses the Enterprise Value to EBIT (EV/EBIT) forward metric for Cytek Biosciences, Inc. (NASDAQ: CTKB). It appears to be an excerpt from a financial data platform, likely TradingView, presenting a specific financial ratio for the company.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB

The article focuses on the enterprise value to revenue forward metric for Cytek Biosciences, Inc. (CTKB) as listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial overview, news, community insights, forecasts, and seasonal trends related to the company's

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 00:11
Source
TradingView
TradingView Direct company coverage

CTKB Forecast — Price Target — Prediction for 2027

The article provides a forecast for Cytek Biosciences, Inc. (CTKB) stock, including analyst price targets and ratings. It details current stock performance, historical highs and lows, and key financial metrics like revenue, earnings, and market capitalization. The article also ad

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

8EQ Forecast — Price Target — Prediction for 2027

This article provides an overview of Cytek Biosciences, Inc. (8EQ) stock, including analyst price targets, financial estimates, and historical performance. It details the company's next earnings report date, past earnings and revenue figures, net income, and confirms that it does

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:11
Source
TradingView
TradingView Direct company coverage

Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB)

This article provides an overview of Cytek Biosciences, Inc. (NASDAQ:CTKB) stock performance, financial data, and analyst forecasts. It covers current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, along with frequently a

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 09:39
Source
TradingView
TradingView Direct company coverage

Cytek Biosciences, Inc. Actuals & Estimates (SWB:8EQ)

This article provides an overview of Cytek Biosciences, Inc. (SWB:8EQ) stock, including financial actuals and estimates for income, balance sheet, and cash flow. It also details analyst price targets, historical stock performance, upcoming earnings dates, and financial metrics li

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:11
Source
TradingView
TradingView Direct company coverage

Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ)

This article provides an overview of Cytek Biosciences, Inc. (GETTEX:8EQ) including its current stock price, market capitalization, financial performance, and analyst forecasts. The stock has shown recent growth, and analysts have set a price target range for its future performan

Tone
Positive 61/100
Event
Analyst action
Published
26 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary

Valerie Barnett will step down from her role as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, effective June 29, 2026. The company stated that her departure is not due to any disagreement with its operations, policies, or practices. Specific details regarding

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:10
Source
TradingView
www.marketscreener.com Direct company coverage

Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026

Cytek Biosciences, Inc. announced the termination of Valerie Barnett's position as Chief Legal Officer and Corporate Secretary, effective June 29, 2026. The company stated that Ms. Barnett's separation is not due to any disagreement with Cytek Biosciences' operations, policies, o

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 16:32
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500

Cytek Biosciences, Inc. (NasdaqGS: CTKB) has been removed from the S&P Composite 1500 index. The announcement was made on June 21, 2026, at 08:57 pm EDT. The article also provides recent news updates about Cytek Biosciences, including board appointments, product innovations, and

Tone
Negative 32/100
Event
Market update
Published
21 Jun 2026 20:57
Source
www.marketscreener.com
The Globe and Mail Direct company coverage

Cytek Biosciences Stockholders Back Board, Pay and Auditor

Cytek Biosciences (CTKB) stockholders recently held their 2026 annual meeting, with strong investor participation. They re-elected three Class II directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm, ensuring continuity

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 17:40
Source
The Globe and Mail
Market source Direct company coverage

Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets

Cytek Biosciences (CTKB) has seen its modelled fair value and average analyst price target reduced due to high operating expenses and an EBITDA shortfall. Despite these cuts, some analysts maintain an Overweight rating citing attractive valuation and potential M&A interest, while

Tone
Negative 38/100
Event
Analyst action
Published
17 Jun 2026 07:39
Source
Market source